Johnson & Johnson splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 27, 2026 was Innovative Medicine at $16.8 billion, 66% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 27, 2026
|
Q3 FY2026
Sep 27, 2026
|
Q2 FY2026
Jun 28, 2026
|
Q1 FY2026
Mar 29, 2026
|
Q4 FY2025
Dec 28, 2025
|
Q3 FY2025
Sep 28, 2025
|
Q2 FY2025
Jun 29, 2025
|
Q1 FY2025
Mar 30, 2025
|
Q4 FY2024
Dec 29, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
99,335
|
25,399
|
25,310
|
24,062
|
24,564
|
23,993
|
23,743
|
21,893
|
22,520
|
| Innovative Medicine |
64,330
+9.1%
share 64.8%
|
16,757
+7.7%
share 66.0%
|
16,384
+7.8%
share 64.7%
|
15,426
+11.2%
share 64.1%
|
15,763
+10.0%
share 64.2%
|
15,563
share 64.9%
|
15,202
share 64.0%
|
13,873
share 63.4%
|
14,332
share 63.6%
|
| Med Tech |
35,005
+5.5%
share 35.2%
|
8,642
+2.5%
share 34.0%
|
8,926
+4.5%
share 35.3%
|
8,636
+7.7%
share 35.9%
|
8,801
+7.5%
share 35.8%
|
8,430
share 35.1%
|
8,541
share 36.0%
|
8,020
share 36.6%
|
8,188
share 36.4%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.